Interleukin-6 (IL-6) has been demonstrated to be involved in Hepatitis B virus (HBV)-associated hepatocarcinogenesis through activation of the STAT3 pathway. The sustained activation of the IL-6/STAT3 pathway is frequently associated with repression of SOCS3, which is both a target gene and a negative regulator of STAT3. However, the silencing mechanism of SOCS3 in hepatocellular carcinoma (HCC) remains to be elucidated. Here, we showed that the repression of SOCS3 and sustained activation of IL-6/STAT3 pathway in HBV-producing HCC cells were caused by HBV-induced mitochondrial ROS accumulation. Mechanistic studies revealed that ROS-mediated DNA methylation resulted in the silencing of SOCS3. Decreased SOCS3 expression significantly promoted the proliferation of HCC cells and growth of tumor xenografts in mice. Further studies revealed that HBVinduced ROS accumulation upregulated the expression of the transcription factor, Snail, which bound to the E-boxes of SOCS3 promoter and mediated the epigenetic silencing of SOCS3 in association with DNMT1 and HDAC1. In addition, we found that the expression of Snail and SOCS3 were inversely correlated in HBV-associated HCC patients, suggesting that SOCS3 and/or Snail could be used as prognostic markers in HCC pathogenesis. Taken together, our data show that HBV-induced mitochondrial ROS production represses SOCS3 expression through Snail-mediated epigenetic silencing, leading to the sustained activation of IL-6/STAT3 pathway and ultimately contributing to hepatocarcinogenesis. Cell Death and Differentiation (2016) 23, 616-627; doi:10.1038/cdd.2015.129; published online 22 January 2016 Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer death in the world.
Interleukin-6 (IL-6) has been demonstrated to be involved in Hepatitis B virus (HBV)-associated hepatocarcinogenesis through activation of the STAT3 pathway. The sustained activation of the IL-6/STAT3 pathway is frequently associated with repression of SOCS3, which is both a target gene and a negative regulator of STAT3. However, the silencing mechanism of SOCS3 in hepatocellular carcinoma (HCC) remains to be elucidated. Here, we showed that the repression of SOCS3 and sustained activation of IL-6/STAT3 pathway in HBV-producing HCC cells were caused by HBV-induced mitochondrial ROS accumulation. Mechanistic studies revealed that ROS-mediated DNA methylation resulted in the silencing of SOCS3. Decreased SOCS3 expression significantly promoted the proliferation of HCC cells and growth of tumor xenografts in mice. Further studies revealed that HBVinduced ROS accumulation upregulated the expression of the transcription factor, Snail, which bound to the E-boxes of SOCS3 promoter and mediated the epigenetic silencing of SOCS3 in association with DNMT1 and HDAC1. In addition, we found that the expression of Snail and SOCS3 were inversely correlated in HBV-associated HCC patients, suggesting that SOCS3 and/or Snail could be used as prognostic markers in HCC pathogenesis. Taken together, our data show that HBV-induced mitochondrial ROS production represses SOCS3 expression through Snail-mediated epigenetic silencing, leading to the sustained activation of IL-6/STAT3 pathway and ultimately contributing to hepatocarcinogenesis. Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer death in the world. 1 Chronic HBV infection and chronic liver disease that progress from hepatitis to cirrhosis are major risk factors for the development of HCC. Options for the treatment of HCC are quite limited because the molecular, cellular and environmental mechanisms that drive HBV-associated HCC pathogenesis are poorly understood.
Pro-inflammatory cytokines contribute significantly to the pathogenesis of many tumor types. 2 Among them, elevated IL-6 is closely related to HCC development and progression. 3 Elevated IL-6 was found in patients with viral and alcoholic hepatitis and liver cirrhosis. In these conditions, IL-6 is expressed mainly by myeloid cells/leukocytes. 4 Recent studies have confirmed that upregulation of IL-6 in human HCC, where it is expressed by the cancer cells, also has a central role in a gene expression network via an autocrine signaling pathway that drives tumor development and progression. 5 However, it remains unknown whether IL-6 autocrine signaling can be stimulated by HBV during hepatocarcinogensis.
Reactive oxygen species (ROS) are continuously generated by cells to regulate cellular responses such as proliferation, differentiation and apoptosis. 6 Chronic virus infection may enhance ROS production and cause oxidative stress in host cells. 7 Continued oxidative stress can lead to IL-6 overexpression through activation of a variety of redox-sensitive transcription factors, such as Nrf2. 8 Interestingly, the sources of ROS are a factor in the specific functions of ROS. 9 For example, ROS generated by mitochondrial respiration are important for pro-inflammatory cytokine production, such as IL-6, whereas ROS generated by other sources, such as NADPH oxidases, may not be able to stimulate the overproduction of pro-inflammatory cytokines. 10 In the IL-6-mediated network, IL-6/STAT3 signaling has a major impact upon cell growth, survival, differentiation and 1 pathogen resistance. 11 Deregulated signaling of IL-6 can cause constitutive activation of STAT3, which promotes the development and progression of HCC. 11 Suppressor of cytokine signaling 3 (SOCS3) is a target gene for STAT3 and also a member of the STAT-induced STAT inhibitor family, which functions as a cytokine-inducible negative regulator of cytokine signaling. 12 The expression of SOCS3 is induced by various cytokines, including IL-6. SOCS3 can bind to and inhibit the activity of JAK2 kinase, thus blocking the activation of STAT3 and controlling the IL-6/STAT3 signaling pathway by a classic negative feedback loop. 12 Recently, reduced expression of SOCS3 has been reported in multiple cancer types, including HCC. [13] [14] [15] This is recognized as the major cause of deregulated IL-6/STAT3 signaling. However, the molecular mechanism of SOCS3 silencing and whether it is implicated in HBV-associated HCC development and progression requires further clarification.
In this study, we revealed that HBV-induced mitochondrial ROS overproduction upregulated the expression of IL-6, leading to the activation of the STAT3 pathway and HCC development. Importantly, our data showed that ROSmediated Snail upregulation repressed SOCS3 expression via hypermethylation of the SOCS3 promoter, contributing to the sustained activation of IL-6/STAT3.
Results
HBV-induced ROS accumulation stimulates the production of IL-6. To determine whether IL-6 was involved in HBVinduced HCC, we examined the expression of IL-6 in HepG2.2.15 cells (which stably express HBV) and HepAD38 cells (which express HBV under tetracycline-off control 16 ). The results showed that both the protein and mRNA expression levels of IL-6 were increased in HBV-producing cells (HepG2.2.15 and non-tetracycline-treated HepAD38) compared with the control cells (HepG2 and tetracyclinetreated HepAD38) (Supplementary Figures 1a and b) . Similarly, elevated protein and mRNA expressions of IL-6 were observed in Hep3B cells with transient transfection of a plasmid containing a 1.3-fold-overlength HBV genome (HBV1.3) (Supplementary Figures 2a and b) . When protein and mRNA expression levels of IL-6 were evaluated in HCC tissues, their levels were higher in liver sections of HBVpositive compared with HBV-negative HCC patients (Supplementary Figures 3a-c) . Similar results were observed in peritumor liver tissues of HBV-positive compared with HBVnegative HCC patients (Supplementary Figures 4a-c) .
ROS has been demonstrated to induce IL-6 overproduction. 9 To determine whether HBV stimulated IL-6 overexpression through induction of ROS levels, the latter was compared between HBV-producing cells and the control cells. The results showed that both H 2 O 2 (as indicated by DCF assay) (Figures 1a and b) and O 2 À (as indicated by dihydroethidium assay) (Figures 1c and d ) levels were increased in HBV-producing cells compared with control cells. To investigate whether HBV could induce ROS levels in vivo, liver lipid peroxidation levels were assessed in HBV-positive and -negative HCC patients. There were increased lipid peroxidation levels in the liver samples of HBV-positive HCC patients compared with HBV-negative HCC patients, suggesting that ROS levels were enhanced in the HBV-infected liver (Figure 1e) .
To investigate the source of HBV-induced ROS levels, HBVproducing cells were treated with selective inhibitors of intracellular sources of ROS. In addition to the general scavenger NAC, apocynin was used to inhibit NAPDH oxidase, nordihydroguaiaretic acid to block 5-lipoxygenase and rotenone to block mitochondrial ROS production. Only NAC and rotenone treatment suppressed intracellular ROS production (Figures 1f and g ), suggesting that the source of HBV-associated elevations in ROS is mitochondria. Likewise, experiments using MitoSOX Red dye, a probe of mitochondrial superoxide production in live cells, showed that mitochondrial ROS levels were higher in HBV-producing cells compared with control cells (Figure 1h ). To determine whether HBV-induced ROS levels affect IL-6 production in liver cells, IL-6 expression levels were determined in HCC cells following H 2 O 2 and NAC treatment. H 2 O 2 (300 μM) increased the IL-6 expression level of non-HBV control cells to a similar level as that of HBVproducing cells, while NAC treatment suppressed IL-6 production in HBV-producing cells, suggesting that HBVinduced IL-6 overproduction was mediated, at least in part, by H 2 O 2 accumulation (Figure 1i ). Taken together, these data indicated that HBV-associated ROS production could enhance IL-6 expression in liver cells both in vitro and in vivo.
Transcriptional factor Nrf2 has been recognized as a sensitive oxidative stress sensor. 17 A recent study demonstrated that IL-6 was a target of Nrf2. 8 To verify whether HBVinduced ROS levels increased IL-6 production through the activation of Nrf2, we measured the protein expression level of Nrf2 and mRNA levels of IL-6, as well as two other Nrf2 target genes, Gclc and Nqo1, in HepG2 and HepG2.2.15 cells (Supplementary Figures 5a and b) . Nrf2 was markedly upregulated by elevated ROS levels and similar results were also observed in mRNA levels of IL-6, Gclc and Nqo1. To confirm that Nrf2 regulated ROS-mediated alterations of IL-6 expression, we blocked the Nrf2 expression in HepG2 and HepG2.2.15 cells with two specific siRNAs. Both protein and mRNA levels of IL-6 were downregulated by underexpression of Nrf2 ( Supplementary Figures 5c and d ), indicating that Nrf2 had a key role in ROS-mediated IL-6 overproduction.
HBV-induced ROS accumulation activates IL-6/STAT3 pathway through epigenetic silencing of SOCS3. STAT3 signaling is one of the most important pathways in HCC development and progression. 11 To determine whether HBVinduced IL-6 overexpression was associated with HCC progression, the activity of STAT3 was determined. As shown in Figure 2a Figures 7a and b) . STAT3 target genes, including Bcl-2, Bcl-xl, Cyclin D1 and VEGF, were also elevated at both the mRNA and protein expression levels, while HBV-induced STAT3 activation was blocked by dexamethasone (an inhibitor of IL-6 expression) (Figure 2a and Supplementary Figure 8) . However, the protein and mRNA expression levels of SOCS3, which is a target gene and negative regulator of STAT3, were unaltered upon IL-6 treatment in HBV-producing cells, but upregulated in non-HBV control cells (Figures 2a and b and Supplementary  Figures 9a and b Supplementary Figures 9c and d) . This indicated that ROS repressed the upregulation of SOCS3 mediated by IL-6. SOCS3 is frequently silenced in cancer cells through epigenetic silencing. 13 To explore the mechanism of SOCS3 repression, the methylation status of the SOCS3 promoter was determined by methylation-specific PCR. As shown in Figure 2e and Supplementary Figure 9e , increased levels of methylated PCR product were identified in HBV-producing HCC cells, as well as control cells treated with H 2 O 2 . In addition, hypermethylation of SOCS3 promoter could be reversed by NAC, suggesting that ROS mediated the methylation process of SOCS3 promoter. Furthermore, a total of 44 CpG sites located between nucleotides -678 and -216 in the SOCS3 promoter were examined by bisulfite sequencing. Dense cytosine methylation was observed in the CpG islands Figure 9f ). These data suggested that the SOCS3 promoter was hypermethylated by HBV-induced ROS accumulation in HCC cells. To further determine whether SOCS3 promoter hypermethylation was responsible for SOCS3 gene silencing, the effect of 5-aza-2'-deoxycytidine (DAC), a demethylating agent, was examined. Treatment with DAC significantly increased the mRNA levels of SOCS3 ( Figure 2g ) and restored the expression of SOCS3 protein (Figure 2h ) in HBV-producing HCC cells. On the other hand, addition of a histone deacetylase (HDAC) inhibitor, trichostatin A, had no effect on the expression of SOCS3 (Figures 2g and h ). However, trichostatin A was found to augment the effect of DAC, indicating that SOCS3 might be regulated by HDACs in a demethylation-dependent manner.
Consistently, similar results were observed in methylation status of SOCS3 promoter upon DAC and trichostatin A treatment ( Figures 2I and j) , suggesting that the impact of these treatments on SOCS3 expression were mediated by methylation of SOCS3 promoter. Taken together, these observations indicated that SOCS3 repression was due to ROS-mediated SOCS3 promoter methylation in HBVproducing HCC cells.
SOCS3 inhibits the growth of HCC cells both in vitro and in vivo. To elucidate the role of SOCS3 in HBV-associated HCC development and progression, SOCS3 was overexpressed in HBV-producing HCC cells that had relatively low endogenous SOCS3 levels. Alternatively, relatively high levels of SOCS3 in control cells were suppressed by the Figures 10c and d) . Moreover, knockdown of SOCS3 repressed apoptotic cell death in control cells, whereas overexpression of SOCS3 increased cell death rate in HBV-producing HCC cells (Figure 3e and Supplementary  Figure 10e) . Collectively, these results indicated that SOCS3 inhibited the proliferation and cell survival of HCC cells.
To determine whether SOCS3 had the same influence on tumor growth in vivo, HCC cells were injected subcutaneously into nude mice. SOCS3 overexpression repressed the tumor growth over the course of the experiment, as indicated by Figures 3f-h ). In addition, immunohistochemistry (IHC) showed less Ki67 staining, more caspase-3 staining and less Cyclin D1 staining in SOCS3-overexpressing HCC cells, indicative of reduced proliferation ( Figures 3I and j) . Moreover, there were fewer blood vessels in SOCS3-overexpressing tumors, suggesting that SOCS3 could repress the cell growth in vivo through inhibition of angiogenesis (Figures 3i and j) . Taken together, these data indicated that SOCS3 inhibits HCC cell growth both in vitro and in vivo.
ROS-induced Snail upregulation is responsible for epigenetic silencing of SOCS3 promoter. To elucidate the mechanism of SOCS3 promoter hypermethylation, biotinlabeled SOCS3 promoter was used as a probe for proteomic analysis of nuclear proteins that could bind to it in HepG2 and HepG2.2.15 cells. This yielded a series of proteins that showed different binding affinities to the SOCS3 promoter in HepG2 compared with HepG2.2.15 cells (Figure 4a ). After bioinformatics analyses of the MS data, Snail was identified as a potential repressor of SOCS3 because Snail mediates the promoter hypermethylation process. 18 Moreover, the expression of Snail could be increased by ROS in HCC cells, 18 suggesting that HBV-induced ROS levels might lead to SOCS3 promoter hypermethylation through the upregulation of Snail. To determine whether HBV-induced ROS accumulation promoted hepatocarcinogenesis through Snail-mediated epigenetic silencing of SOCS3, Snail was overexpressed in control cells that had relatively low endogenous Snail levels. Alternatively, relatively high levels of Snail in HBV-producing HCC cells were suppressed by the introduction of specific shRNAs. As shown in Supplementary Figure 12a , Snail overexpression repressed SOCS3 levels in control cells, whereas inhibition of Snail expression increased SOCS3 levels in HBV-producing HCC cells. As indicated by proliferation tests and colony formation assay, Snail-mediated silencing of SOCS3 enhanced cell proliferation in control cells, whereas inhibition of Snail expression negatively regulated cell proliferation in HBV-producing HCC cells (Supplementary Figures 12b-d) . In addition, overexpression of Snail repressed apoptotic cell death in control cells, whereas knockdown of Snail increased cell death rate in HBV-producing HCC cells (Supplementary Figure 12e) . Collectively, these results indicated that Snail inhibited the proliferation and cell survival of HCC cells through the modulation of SOCS3 expression.
Snail represses SOCS3 expression through binding to the E-boxes of SOCS3 in association with HDAC1 and DNMT1. To investigate the mechanism of Snail-mediated SOCS3 promoter hypermethylation, we analyzed the sequence of SOCS3 promoter and identified three E-boxes, which have been demonstrated to serve as the DNA-binding sites of Snail. 19 To determine whether Snail could bind to SOCS3 promoter, the interaction between Snail and SOCS3 promoter was determined by chromatin immunoprecipitation (IP) assay. The results showed that the SOCS3 promoter could bind with Snail and that this binding depended on the Snail expression level (Figure 5a ). Snail has been demonstrated to recruit HDAC1 and DNMT1 during the silencing process of its target. 18 To determine whether this epigenetically modified complex, Snail/HDAC1/DNMT1, participated in the silencing process of SOCS3, experiments were designed to determine complex localization with immunofluorescence. The results showed nuclear co-localization of Snail, HDAC1 and DNMT1 in HepG2.2.15 cells, suggesting that they had the potential to form a complex (Figure 5b ). In addition, IP data showed that Snail, HDAC1 and DNMT1 could bind with each other in HCC cells, reconfirming their interaction (Figure 5c ). Moreover, the interaction between HDAC1, DNMT1 and SOCS3 promoter was verified by chromatin IP assay, which revealed that their interactions with SOCS3 promoter also depended on the Snail expression level, suggesting that Snail was crucial for the recruitment of Snail/HDAC1/DNMT1 complex to the promoter of SOCS3 (Figure 5a ). To verify whether the E-boxes of SOCS3 were the binding sites of Snail, biotinylated double-stranded oligonucleotides corresponding to the wild type and mutant E-boxes of SOCS3 promoter were used to precipitate Snail from Snail-overexpressing HepG2 cells (Figure 5d ). The results showed that mutation in either E-box significantly reduced the binding between Snail and SOCS3 promoter, indicating that all three E-boxes of the SOCS3 promoter were crucial for Snail binding (Figure 5e ). Studies were then performed to compare the ability of Snail to repress different reporter constructs carrying combinations of mutated E-boxes (Figure 5f ). The results showed that mutation of either E-box impaired the SOCS3 promoter activity and that the furthest downstream E-box (E-box 3) had the strongest repressive activity, suggesting that the three E-boxes cooperated in the Snail-mediated SOCS3 repression.
SOCS3 and Snail expression are negatively correlated and could serve as prognostic factors in HBV-associated HCC. To elucidate the clinical relevance of SOCS3 and Snail, their expression levels were analyzed in clinical liver cancer samples. SOCS3 was shown to be downregulated in HBV-positive HCC tissue samples compared with HBVnegative ones by IHC and immunoblot analysis (Figures 6a  and b) . In contrast, Snail was overexpressed in HBV-positive HCC tissue samples. Statistical analysis of the IHC quantification data further demonstrated a significant inverse correlation between these markers in HCC samples (Figure 6c ). This inverse correlation was also observed in peritumor liver tissues in HBV-positive and HBV negative patients with HCC ( Supplementary Figures 13a-d) . Methylation-specific PCR (Figure 6d ) and bisulfite sequencing (Figure 6e ) analysis revealed that the SOCS3 promoter was hyper-methylated in HBV-positive HCC tissue samples, which is consistent with the high expression levels of Snail.
The pathological relevance of SOCS3 and Snail expression in HBV-associated HCC was then examined by IHC. On the basis of the IHC quantification data (Figure 6c ), we found that low levels of SOCS3 or high levels of Snail expression were correlated with poorly differentiated tumors. In addition, SOCS3 expression correlated with sex and HBsAg expression.
By contrast, neither SOCS3 nor Snail expression correlated with age (Supplementary Table 1) . HCC patients were then grouped based on the expression levels of SOCS3 and Snail. Log-rank analysis demonstrated that the high SOCS3-expressing group experienced longer overall survival and disease-free survival when compared with the low SOCS3-expressing group, whereas the high Snail-expressing group experienced shorter overall survival and disease-free survival when compared with the low Snail-expressing group (Figures 6f and g ). Univariate and multivariate analyses Table 2 ). To determine whether the combination of SOCS3 and Snail could be used as a prognostic factor in predicting the outcome of HBV-associated HCC, patients were classified into four groups according to SOCS3 and Snail expression: group 1 (n = 53): high SOCS3 and Snail expression; group 2 (n = 51): high SOCS3 but low Snail expression; group 3 (n = 59): low SOCS3 but high Snail expression; and group 4 (n = 65): low SOCS3 and Snail expression. Differences in both overall survival (Po0.001) and disease-free survival (Po0.001) were significant among the four groups and group 3 indicated the worst prognosis (Figure 6h) .
To further elucidate the correlation between SOCS3 promoter methylation and HBV-induced hepatocarcinogenesis, bisulfite sequencing analyses were performed to examine the SOCS3 promoter methylation status of all four groups (n = 30 in each group). As shown in Supplementary   Figure 14a , the HBV status in the four different groups is as follows: group 1 (HBV-, n = 11; HBV+, n = 19); group 2 (HBV-, n = 19; HBV+, n = 11); group 3 (HBV-, n = 0; HBV+, n = 30); group 4 (HBV-, n = 0; HBV+, n = 30). The percentage of HBVpositive and -negative patients that show SOCS3 promoter methylation was 86.7% and 10%, respectively. Moreover, SOCS3 promoter methylation was positively correlated with Snail protein levels, whereas negatively correlated with SOCS3 protein levels (Supplementary Figures 14b and c) , suggesting that Snail mediated SOCS3 promoter methylation in HBV-associated HCC patients.
Discussion
Over the past 10 years, studies have produced compelling evidence for the functionally important tumor-promoting effects that inflammation can have on neoplastic progression. 20 Importantly, inflammation is clearly capable of fostering the development of incipient neoplasias and full-blown cancers. 21 In addition, inflammatory cells have been demonstrated to release chemicals, including ROS, that are mutagenic for nearby cancer cells, accelerating the development and progression of malignancy. 22 However, the linkage between inflammation and ROS remains unclear. In this study, we found that HBV-induced ROS accumulation could promote inflammation through the upregulation of IL-6 expression in HCC. Moreover, elevated ROS deregulated the IL-6/STAT3 signaling pathway, leading to the constitutive activation of STAT3. Taken together, these results demonstrated that ROS has a key role in promoting the inflammation-mediated hepatocarcinogenesis.
SOCS3 is a target of STAT3, which in turn suppresses the activation of STAT3 through negative feedback. 12 Accumulating evidence has revealed that SOCS3 is epigenetically silenced, resulting in the hyper-activation of STAT3 in many cancers, such as cholangiocarcinoma, 13 head and neck squamous cell carcinoma 23 and HCC. 14 However, the epigenetic mechanism underlying SOCS3 repression has not been elucidated. Here, we showed that SOCS3 and Snail (bottom) expression levels. (g) Cumulative disease-free survival curves of patients with high or low SOCS3 (top) and Snail (bottom) expression levels. (h) Cumulative overall (top) and disease-free (bottom) survival curves of the combination of SOCS3 and Snail. HCC patients were classified into four groups according to SOCS3 and Snail expression: group 1 (n = 53): high SOCS3 and Snail expression; group 2 (n = 51): high SOCS3 but low Snail expression; group 3 (n = 59): low SOCS3 but high Snail expression; and group 4 (n = 65): low SOCS3 and Snail expression expression could be downregulated by HBV-induced ROS production through promoter hypermethylation. In addition, demethylation of SOCS3 promoter by DAC restored the SOCS3 expression, which in turn repressed the activation of STAT3, suggesting that the function of SOCS3 as a STAT3 target and negative regulator was controlled by its promoter methylation status. More importantly, we identified Snail as a repressor of SOCS3, which could bind SOCS3 promoter through E-boxes and mediate the methylation process of SOCS3 promoter in association with DNMT1 and HDAC1, similar to the epigenetic silencing process found for E-cadherin. 18 These findings indicated that Snail functions as an essential initiating factor which can promote cancer development and progression through epigenetic silencing of certain tumor suppressors, such as SOCS3.
The pathological relevance of the IL-6/STAT3 signaling pathway has been observed in many types of human cancer, and Snail is a validated drug target for treating human cancer. However, IL-6/STAT3 signaling and the Snail-mediated tumor initiation and progression have, to date, been considered as remote pathways. 24 The studies herein support the notion that Snail has a regulatory role in the IL-6/STAT3 signaling pathway through hypermethylation of the SOCS3 promoter. As the expression of Snail negatively correlates with HBV-associated HCC patient outcome, while the expression of SOCS3 is positively correlated, it is tempting to speculate that the combination of Snail and SOCS3 may have prognostic value in the prediction of both survival and recurrence. However, it remains to be seen whether the combination of Snail and SOCS3 expression has a better power to predict HBVassociated HCC patient outcome than the prognostic factors that have been used in the clinic, such as alpha-fetoprotein. 25 In conclusion, this study has revealed that HBV-induced mitochondrial ROS production stimulates IL-6 expression, which activates STAT3 pathway through autocrine signaling. More importantly, ROS accumulation upregulates Snail expression, which then leads to sustained activation of the IL-6/STAT3 pathway through epigenetic silencing of SOCS3, finally contributing to hepatocarcinogenesis (Figure 7) . Further studies will be required to investigate whether the hepatocarcinogenesis process, which is mediated by HBVinduced ROS accumulation, can be observed in HBV transgenic mice that mimic development of human HCC. 26 Materials and Methods Cell lines. HepG2, HepG2.2.15 and HepAD38 cells were cultivated in Dulbecco's modified Eagle's medium (Gibco, Grand Island, NY, USA) containing 10% FBS (Hyclone, Logan, UT, USA), penicillin (10 7 U/l) and streptomycin (10 mg/l) at 37°C and 5% CO 2 . For HepAD38 cells, the medium was further supplemented with 400 μg/ml G418 and 2 μg/ml tetracycline. Confluent HepAD38 cells were washed with prewarmed PBS and then transferred to medium without tetracycline in which the replication of wild-type HBV was induced. 16 Assays of reactive oxygen species. The intracellular levels of H 2 O 2 and O 2 -were measured with 2′, 7′-dichlorofluorescin diacetate and dihydroethidium, respectively. Mitochondrial ROS production was detected by the MitoSOX Red assay (Life Technologies, Grand Island, NY, USA). Fluorescence was detected by Fluorometer (Thermo Fisher, Waltham, MA, USA).
Lipid peroxidation assay. Malondialdehyde is an end product of the lipid peroxidation process and was measured using a colorimetric assay (Calbiochem, San Diego, CA, USA) according to the manufacturer's instructions. Homogenized liver tissue in 62.5 mM Tris-HCl (pH = 6.8) supplemented with Complete Mini protease inhibitor (Roche Diagnostics, Indianapolis, IN, USA) at equivalent protein amounts was used in the assay. 27 Clinical specimens. All HCCs and corresponding adjacent normal tissues were obtained from de-identified patients who had undergone surgical resections at Figure 7 A mechanism of hepatocarcinogenesis promotion via HBV-induced ROS accumulation. HBV replication induces intracellular ROS levels. Elevated ROS production then increases IL-6 production. IL-6 overexpression activates STAT3 via autocrine signaling, which causes increased expressions of a series of oncogenes, such as Bcl-2, Bcl-xl, Cyclin D1 and VEGF. Commonly, IL-6/STAT3 pathway is negatively regulated by SOCS3, a target gene of STAT3, through a negative feedback loop. However, HBV-induced ROS overproduction can increase the expression of Snail, which silences SOCS3 expression via hypermethylation of SOCS3 promoter and leads to constitutive activation of STAT3, finally contributing to hepatocarcinogenesis of HBV-associated HCC West China Hospital (Chengdu, China) or Sichuan Provincial People's Hospital (Chengdu, China). All paired samples were immediately frozen in liquid nitrogen. Ethics approval was obtained from the Institutional Ethics Committee of Sichuan University. Tumor differentiation was characterized according to WHO classification, while the pathologic stage was analyzed according to the TNM classification system of the International Union against Cancer. 28 Clinico-pathological information for these patients is summarized in Supplementary Table 1 .
Methylation-specific PCR. Genomic DNA was extracted and subjected to bisulfite modification as described previously. 29 Briefly, 2 μg of genomic DNA was denatured with 0.2 M NaOH at 37°C for 10 min and treated with 10 mM hydroquinone and 3 M sodium bisulfite (pH 5.0) at 50°C for 16 h. Modified genomic DNA was analyzed with methylation-specific PCR SOCS3 primers as described. 13 The positions and sequences of the primers are shown in Supplementary Figures  15a and b. Bisulfite sequencing. DNA obtained from surgical samples and cells was treated with bisulfite modification and examined for the methylation status of 44 CpG dinucleotides within the SOCS3 gene promoter region as described previously. 13 The SOCS3 gene promoter was amplified from the bisulfite-modified DNA by two rounds of PCR using nested primers specific to the bisulfite-modified sequence of the SOCS3 gene CpG island. The positions and sequences of the primers are shown in Supplementary Figures 15a and b .
Proliferation assays. Cell viability was measured using the Cell Counting Kit-8 (CCK-8; Beyotime, Nanjing, China). Intracellular bromodeoxyuridine incorporation assay was performed according to the manufacturer's instruction (BD Pharmingen, San Diego, CA, USA).
Soft-agar colony formation assay. A total of 5 × 10 4 cells were suspended in Dulbecco's modified Eagle's medium containing 0.35% agarose and layered on solidified medium containing 0.7% agarose in six-well plates. The medium was replaced every week. Images were taken after 2 weeks and analyzed with ImageJ software.
TUNEL assay. Apoptotic cell death was measured by TUNEL assay according to the manufacturer's instruction (Promega, Madison, WI, USA).
Tumor xenograft model. Male mice (BALB/c, 6 weeks of age) (HFK Bio, Beijing, China) were injected subcutaneously with HCC cells (1 × 10 7 cells per mouse). Tumor measurements were taken by caliper every 3 days. The tumor volumes were determined by measuring the length (l) and the width (w) and calculating the volume (V = lw 2 /2). After 18 days, the mice were killed and tumors were excised, pictured and weighed. Use of mice for this study was approved by the Institutional Animal Care and Use Committee (IACUC) at Sichuan University.
Biotinylated oligonucleotide precipitation assay. DNA precipitations were carried out as described previously. 30 The biotinylated double-stranded wildtype and mutated SOCS3 oligonucleotide sequences are indicated in Supplementary Table 3 . DNA-bound proteins were collected with streptavidinagarose beads (Pierce, Rockford, IL, USA) and analyzed by western blotting.
Chromatin immunoprecipitation. Chromatin IP assay was carried out as described previously. 31 Immunoprecipitated DNA was quantitated by real-time quantitative PCR. Primer sets were chosen to amplify approximately 100 to 150 base pairs on the promoter of SOCS3. The enrichments of Snail, HDAC1 and DNMT1 at the examined regions were quantitated relative to the input amount. The positions and sequences of the primers are shown in Supplementary  Figures 15a and b. 
